Showing results (181-190 of 226) with videos related to
Sort By:
Pageof 23
Gut|January 9, 2015
Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international studyPalak J Trivedi, Willem J Lammers, Henk R van Buuren, et al.JHEP Reports : Innovation in Hepatology|March 8, 2021
Real-world experience with obeticholic acid in patients with primary biliary cholangitisDaphne D'Amato, Antonio De Vincentis, Federica Malinverno, et al.Clinical and Experimental Rheumatology|May 19, 2017
Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants todayFilippo Bartalesi, Carlo Scirè, Ana Requena-Méndez, et al.Frontiers in Immunology|April 16, 2014
Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosisCarlo Selmi, Francesca Cavaciocchi, Ana Lleo, et al.Liver International : Official Journal of the International Association for the Study of the Liver|August 6, 2022
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acidAntonio De Vincentis, Daphne D'Amato, Laura Cristoferi, et al.Nature Communications|September 23, 2015
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathwaysHeather J Cordell, Younghun Han, George F Mells, et al.Annals of Hepatology|August 15, 2024
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinomaLouisa Stern, Constantin Schmidt, Lorenz Kocheise, et al.Gastroenterology|August 12, 2015
Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid TherapyWillem J Lammers, Gideon M Hirschfield, Christophe Corpechot, et al.Journal of Hepatology|June 23, 2022
Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic targetGiorgia Alvisi, Alberto Termanini, Cristiana Soldani, et al.Signal Transduction and Targeted Therapy|April 28, 2026
MARCO promotes cholangiocarcinogenesis by inducing immunosuppression and its targeting reduces tumor growthAloña Agirre-Lizaso, Maider Huici-Izagirre, Colm J O'Rourke, et al.Pageof 23